Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) went down by -0.69% from its latest closing price compared to the recent 1-year high of $5.33. The company’s stock price has collected -1.38% of loss in the last five trading sessions. Press Release reported on 09/23/20 that Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Is It Worth Investing in Lexicon Pharmaceuticals Inc. (NASDAQ :LXRX) Right Now?
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) scored a price-to-earnings ratio above its average ratio, recording 7.65 x from its present earnings ratio. Plus, the 36-month beta value for LXRX is at 1.36. Opinions of the stock are interesting as 1 analysts out of 5 who provided ratings for Lexicon Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $2.70. LXRX currently public float of 101.51M and currently shorts hold a 11.65% ratio of that float. Today, the average trading volume of LXRX was 1.68M shares.
LXRX’s Market Performance
LXRX stocks went down by -1.38% for the week, with a monthly drop of -18.29% and a quarterly performance of -26.29%, while its annual performance rate touched -56.40%. The volatility ratio for the week stands at 7.35% while the volatility levels for the past 30 days are set at 5.71% for Lexicon Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -8.89% for LXRX stocks with a simple moving average of -39.13% for the last 200 days.
Analysts’ Opinion of LXRX
Citigroup, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $4, previously predicting the price at $3. The rating they have provided for LXRX stocks is “Neutral” according to the report published on November 08th, 2019.
Gabelli & Co gave a rating of “Buy” to LXRX, setting the target price at $3 in the report published on September 11th of the previous year.
LXRX Trading at -17.11% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.17% of loss for the given period.
Volatility was left at 5.71%, however, over the last 30 days, the volatility rate increased by 7.35%, as shares sank -14.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.91% lower at present.
During the last 5 trading sessions, LXRX fell by -1.38%, which changed the moving average for the period of 200-days by -70.52% in comparison to the 20-day moving average, which settled at $1.5575. In addition, Lexicon Pharmaceuticals Inc. saw -65.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- +52.81 for the present operating margin
- +98.42 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc. stands at +40.40. The total capital return value is set at 58.39, while invested capital returns managed to touch 45.67. Equity return is now at value 48.20, with 10.10 for asset returns.
Based on Lexicon Pharmaceuticals Inc. (LXRX), the company’s capital structure generated 210.83 points at debt to equity in total, while total debt to capital is 67.83. Total debt to assets is 58.52, with long-term debt to equity ratio resting at 200.91. Finally, the long-term debt to capital ratio is 64.64.
Currently, EBITDA for the company is -62.08M with total debt to EBITDA at 1.41. When we switch over and look at the enterprise to sales, we see a ratio of 1.43, with the company’s debt to enterprise value settled at 0.54. The receivables turnover for the company is 10.31 and the total asset turnover is 0.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.17.